“And that we will submit for U.S. approval for tirzepatide in adults with obesity and heart failure with Preserved Ejection Fraction before the end of this year.”

In context

“nearly 23% during the more than three-year treatment period and that this weight loss was accompanied by a significant reduction in risk of developing diabetes. We look forward to sharing the detailed results next week at ObesityWeek. These results add to compelling data showing the benefit of the combined pharmacology of dual GIP and GLP-1 receptor agonism in several obesity-related complications, including Type-2 diabetes, metabolic dysfunction-associated steatohepatitis or MASH, moderate-to-severe obstructive sleep apnea, and heart failure. We are working quickly to bring tirzepatide to more adults living with obesity and its complications, and we are pleased to share that we expect U.S. regulatory action for tirzepatide in adults with obesity and obstructive sleep apnea yet this year. And that we will submit for U.S. approval for tirzepatide in adults with obesity and heart failure with Preserved Ejection Fraction before the end of this year. Another avenue to advance patient care is the maintenance of body weight reductions. We are conducting two Phase 3b weight loss maintenance trials. The first is SURMOUNT-MAINTAIN, which compares either tirzepatide 5 milligrams or tirzepatide maximum tolerated dose to placebo. The second is ATTAIN-MAINTAIN, which evaluates our oral GLP-1 orforglipron versus placebo after tirzepatide or semaglutide in participants who completed SURMOUNT-5, the 3b head-to-head study of tirzepatide versus semaglutide. We look forward to sharing the topline data readout for SURMOUNT-5 later this year. Next, in oncology. The Phase 3 EMBER-3 study evaluating our oral SERD, imlunestrant, in patients with second-line ER positive HER2 negative metastatic breast cancer was positive. The study evaluated three-arms, i”